Compare OLN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OLN | RAPP |
|---|---|---|
| Founded | 1892 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 1994 | 2024 |
| Metric | OLN | RAPP |
|---|---|---|
| Price | $16.77 | $40.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $25.23 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 2.6M | 263.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,780,800,000.00 | N/A |
| Revenue This Year | $2.57 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $16.68 | $23.75 |
| 52 Week High | $30.46 | $52.93 |
| Indicator | OLN | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 33.60 |
| Support Level | $16.73 | $38.95 |
| Resistance Level | $18.29 | $43.99 |
| Average True Range (ATR) | 0.62 | 1.96 |
| MACD | 0.07 | -0.88 |
| Stochastic Oscillator | 7.10 | 3.81 |
Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.